Dispensing Talzenna + Vizimpro

November 1, 2018

Dispensing Talzenna + Vizimpro

Onco360 is dispensing two new Pfizer oncology medications, TALZENNA® and VIZIMPRO®.

TALZENNA (talazoparib) is a once-daily oral treatment indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Full Prescribing Information

VIZIMPRO (dacomitinib) is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). VIZIMPRO is used as a first treatment if your tumor has certain types of abnormal epidermal growth factor receptor (EGFR) gene(s). Full Prescribing Information

Community and hospital-based oncologists can immediately place prescription orders with Onco360 for TALZENNA and VIZIMPRO, as well as other cancer and supportive care medications. Onco360 will work with your practice to verify your patients’ benefits, coordinate prior authorizations and copay assistance as needed, and keep you and your patients updated on the status of their dispense. 

Refer Your Patients to Onco360